finerenone
finerenone
Overview
Finerenone is a non-steroidal mineralocorticoid receptor antagonist used as a therapy in cardiorenal disease. By antagonizing mineralocorticoid receptor signaling, it is associated with anti-inflammatory and anti-fibrotic effects, which are relevant to diseases characterized by progressive kidney injury, albuminuria, fibrosis, and cardiovascular complications. In recent biomedical literature, finerenone has been studied primarily in the context of diabetic kidney disease (DKD) and heart failure, with expanding interest in other chronic kidney disease populations.
Unlike older steroidal mineralocorticoid receptor antagonists, finerenone has been developed as a more selective non-steroidal agent and has attracted attention for its potential to improve both renal and cardiovascular outcomes. Recent studies also suggest broader mechanistic relevance to pathways such as autophagy pathways and tissue fibrosis, including work in peritoneal fibrosis and myocardial remodeling.
Focus of Latest Publications
Recent publications on finerenone have focused heavily on real-world effectiveness and safety in cardiorenal disease, especially diabetic kidney disease (DKD) and chronic kidney disease (CKD) associated with type 2 diabetes. Several observational studies examined finerenone use in routine practice, including cohorts from China and Saudi Arabia, as well as analyses of prescribing patterns in the United States. These reports were motivated by the fact that, although finerenone has shown cardiorenal benefit in randomized trials, real-world evidence remains limited in some populations and settings. One U.S. analysis also highlighted that finerenone appears infrequently used in clinical practice despite its established role in reducing kidney disease progression, cardiovascular events, and heart failure outcomes.
Other recent studies explored whether patient characteristics modify finerenone’s renal effects. In CKD associated with type 2 diabetes, one study evaluated whether pre-treatment estimated glomerular filtration rate trajectory influences finerenone’s renoprotective effect on kidney function and albuminuria. Another study in people with CKD, type 2 diabetes, and a history of nephrectomy reported that finerenone reduced albuminuria versus placebo capsules similarly in patients with and without nephrectomy, with generally comparable treatment-emergent and serious adverse event rates. Additional work in IgA nephropathy assessed finerenone both with ACEI/ARB therapy and in combination with sodium glucose cotransporter-2 (SGLT2) inhibitors, reflecting interest in how finerenone may fit into broader renoprotective regimens.
Finerenone has also been studied beyond kidney disease. In heart failure with mildly reduced or preserved ejection fraction, investigators assessed the transportability of the FINEARTS-HF trial to a real-world U.S. population and performed a Bayesian analysis of efficacy and safety, both reinforcing the relevance of the trial findings for clinical practice. In a swine model of repetitive pressure overload, oral finerenone reduced myocardial interstitial fibrosis but did not improve left ventricular chamber stiffness, suggesting that antifibrotic effects may not directly translate into improved diastolic mechanics in that model. Another preclinical study examined finerenone in peritoneal fibrosis, aiming to determine whether it alleviates fibrosis by restoring autophagy flux in peritoneal mesothelial cells.
A smaller number of publications extended finerenone research into other experimental settings. One rat study examined finerenone, alone or with bosentan, in a model involving benign prostatic hyperplasia and cardiac dysfunction. Another medicinal chemistry paper discussed mineralocorticoid receptor antagonists in the context of finerenone’s approval and ongoing interest in this drug class, but did not evaluate finerenone itself experimentally. Overall, the recent literature emphasizes finerenone’s expanding real-world use, its role in DKD and CKD, and continued investigation of its effects in heart failure and fibrotic disease models.